A severe refractory COVID-19 patient responding to convalescent plasma; A case series

Link to article at PubMed

Abdullah HM, et al. Ann Med Surg (Lond) 2020.

ABSTRACT

INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP).

CASE REPORT: Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests.

CONCLUSION: CP might be an effective therapy for severe COVID-19 patients.

PMID:32637086 | PMC:PMC7327024 | DOI:10.1016/j.amsu.2020.06.018

Leave a Reply

Your email address will not be published.